Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation

The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers...

Full description

Saved in:
Bibliographic Details
Other Authors: Bodis, Stephan (Editor), Ghadjar, Pirus (Editor), Van Rhoon, Gerard C. (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_87516
005 20220706
003 oapen
006 m o d
007 cr|mn|---annan
008 20220706s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-4531-8 
020 |a 9783036545325 
020 |a 9783036545318 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-4531-8  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
072 7 |a MJCL  |2 bicssc 
100 1 |a Bodis, Stephan  |4 edt 
700 1 |a Ghadjar, Pirus  |4 edt 
700 1 |a Van Rhoon, Gerard C.  |4 edt 
700 1 |a Bodis, Stephan  |4 oth 
700 1 |a Ghadjar, Pirus  |4 oth 
700 1 |a Van Rhoon, Gerard C.  |4 oth 
245 1 0 |a Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (346 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers and a long term follow-up. Therefore we need more level I EVIDENCE from clinical trials, we need HARMONISATION and global acceptance for existing technologies and a common language understood by all stakeholders and we need INNOVATION in the fields of biology, clinics and technology to move thermotherapy/hyperthermia forward. This is the main focus of this reprint. In this reprintyou find carefully selected and peer-reviewed contributions from Africa, America, Asia, and Europe. The published papers from leading scientists from all over the world covering a broad range of timely research topics might also help to strengthen thermotherapy on a global level. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Oncology  |2 bicssc 
653 |a perfusion estimation 
653 |a temperature monitoring 
653 |a conductivity reconstruction 
653 |a systems medicine 
653 |a immune system in silico 
653 |a perceptron 
653 |a antigen pattern 
653 |a danger signal 
653 |a fractionation 
653 |a immune response 
653 |a head and neck cancer 
653 |a hyperthermia 
653 |a reirradiation 
653 |a treatment outcome 
653 |a hyperthermia treatment planning 
653 |a adaptive planning 
653 |a temperature optimization 
653 |a low-middle-income group countries 
653 |a cancer 
653 |a radiotherapy 
653 |a chemotherapy 
653 |a recurrent breast cancers 
653 |a cervical cancer 
653 |a head and neck cancers 
653 |a cost-effective 
653 |a meta-analysis 
653 |a intensity-modulated radiotherapy 
653 |a prostate cancer 
653 |a thermal dose 
653 |a thermometric parameters 
653 |a preclinical data 
653 |a clinical evidence 
653 |a modulated electro-hyperthermia 
653 |a abscopal effect 
653 |a locally advanced cervical cancer 
653 |a resource-constrained setting 
653 |a radiosensitiser 
653 |a rectal cancer 
653 |a chemoradiotherapy 
653 |a tumour control 
653 |a loco-regional hyperthermia 
653 |a oncology 
653 |a cellular selection 
653 |a bioelectromagnetics 
653 |a complexity 
653 |a immune-effects 
653 |a moderate hyperthermia 
653 |a deep hyperthermia 
653 |a radiative hyperthermia 
653 |a patterns of care 
653 |a reimbursement 
653 |a regional hyperthermia 
653 |a neoadjuvant chemoradiation 
653 |a survival 
653 |a induced 
653 |a brachytherapy 
653 |a prostatic neoplasms 
653 |a interstitial hyperthermia 
653 |a treatment plan optimization 
653 |a prostate 
653 |a thermoradiotherapy 
653 |a linear quadratic model 
653 |a biological modeling 
653 |a thermal dosimetry 
653 |a hypoxia 
653 |a radiation therapy 
653 |a reoxygenation 
653 |a perfusion 
653 |a oxygen consumption rate 
653 |a local tumor control 
653 |a biomarker 
653 |a immune phenotype 
653 |a hyperthermia treatment sequence 
653 |a breast cancer 
653 |a immune checkpoint molecules 
653 |a dendritic cell activation 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/5714  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/87516  |7 0  |z DOAB: description of the publication